BioSpace News Archive

Pictured: Facade of Moderna's building in Massachusetts

Moderna Scales Back COVID Vaccine Production, Pursues mRNA Medicines Plan

The company plans to launch up to 15 new products and bring up to 50 new candidates to the clinic over the next five years as part of its growth plan, while scaling down COVID-19 manufacturing.

September 13, 2023

·

3 min read

·

Kate Goodwin

Two scientists collaborating in a laboratory_iStoc

Postdoc Programs at Pharmaceutical Companies: A Research Path Less Chosen

Postdoctoral programs in industry are often overlooked by PhD candidates but they provide certain benefits over academic positions, including better pay.

September 13, 2023

·

4 min read

·

Sanjukta Mondal

Drug Development

Alnylam Wins Adcomm’s Support for Heart Disease Drug Despite FDA Concerns

The Cardiovascular and Renal Drugs Advisory Committee voted 9-3 in favor of Alnylam’s patisiran on whether its benefits outweigh its risks for patients with cardiomyopathy induced by transthyretin amyloidosis.

September 13, 2023

·

3 min read

·

Hayley Shasteen

Pictured: X-ray illustration with the adrenal glan

Drug Development

Neurocrine’s Congenital Adrenal Hyperplasia Candidate Clears Phase III

Topline data for the company’s CRF1 antagonist crinecerfont showed a significant drop in daily glucocorticoid dose, while maintaining androgen control in adult patients with the genetic disorder.

September 13, 2023

·

2 min read

·

Tristan Manalac

Update: AbbVie headquarters building in California

Drug Development

AbbVie’s Skyrizi Outperforms J&J’s Stelara in Late-Stage Crohn’s Disease Trial

Continuing its clinical win streak, AbbVie’s Skyrizi showed signs of superiority against Johnson & Johnson’s Stelara in topline data from a head-to-head Phase III Crohn’s disease study.

September 13, 2023

·

2 min read

·

Tristan Manalac

Pictured: Illustration of liver surrounded by hepa

Drug Development

Eiger Discontinues Phase III Hepatitis Study Due to Safety Concerns

Following cases of hepatobiliary toxicity leading to liver decompensation, Eiger has decided to drop its Phase III LIMT-2 trial of peginterferon lambda in chronic hepatitis delta.

September 13, 2023

·

2 min read

·

Tristan Manalac

Biotech Bay

Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced positive topline results from its ColoFuture study.

September 13, 2023

·

7 min read

Business

Myricx Expands its Leadership Team with the Appointment of Dr. Robert McLeod as VP Clinical Development

Myricx Bio announces the appointment of Dr. Robert McLeod as Vice President Clinical Development.

September 13, 2023

·

3 min read

Biotech Beach

Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies

Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, announced the completion of its business combination with First Light Acquisition Group, a special purpose acquisition company.

September 13, 2023

·

11 min read

Business

Culture Biosciences Appoints Darcy Birse as Chief Commercial Officer

Culture Biosciences , a leading provider of innovative, future-forward bioprocessing solutions, is pleased to announce the appointment of Darcy Birse as the company’s new Chief Commercial Officer (CCO).

September 13, 2023

·

3 min read